The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia

Fludarabine treatment in patients with B-cell chronic lymphocytic leukemia (B-CLL) can trigger or exacerbate the development of autoimmune hemolytic anemia (AHA) through a currently ill-defined mechanism. We here show that exposure of peripheral blood lymphocytes from healthy donors and B-CLL patien...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2006-04, Vol.91 (4), p.574
Main Authors: Gamberale, R, Fernandez-Calotti, P, Sanchez-Avalos, J, Alberto, MF, Geffner, J, Giordano, M
Format: Article
Language:English
Subjects:
Anemia, Hemolytic, Autoimmune - chemically induced
Anemia, Hemolytic, Autoimmune - etiology
Case-Control Studies
Humans
Interferon-gamma - biosynthesis
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Lymphocytes - drug effects
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
Vidarabine - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fludarabine treatment in patients with B-cell chronic lymphocytic leukemia (B-CLL) can trigger or exacerbate the development of autoimmune hemolytic anemia (AHA) through a currently ill-defined mechanism. We here show that exposure of peripheral blood lymphocytes from healthy donors and B-CLL patients to fludarabine increases in vitro production of interferon-gamma, a key cytokine in the pathogenesis of AHA.
ISSN:0390-6078
1592-8721